Cavinton vinpocetine tablet, drug treatment, benefit and side effects

March 5 2014

Cavinton is the name for vinpocetine used by researchers in Russia, Bulgaria, and eastern European countries. Cavinton has shown some promise for stroke related conditions. Cavinton improves blood flow to the brain, ear, and eyes. The optimal dosage for various medical conditions is not fully known. Most studies have used dosages of 10 mg three times daily, but Cavinton side effects could occur on these dosages. We suggest you first begin taking vinpocetine at 5 mg a day and then monitor your progress, benefits, and side effects over a few days before increasing or decreasing your dosage. Potential Cavinton side effects include dizziness, lightheadedness, malaise, and weakness.

Vinpocetine 5 mg and 10 mg capsules

Vinpocetine capsule has been sometimes recommended for more than once daily however many people may be sensitive to this supplement and would do fine using half a capsule. By taking a small amount of vinpocetine at first, you could avoid a side effect.

Vinpocetine 5 mg and 10 mg capsules



Buy Vinpocetine 5 mg

Cavinton for eyes
Effect of vasoactive agents on visual functions and ocular blood flow in patients with early manifestations of age-related macular degeneration.
Vestn Oftalmol. 2007.
Forty patients aged 40 to 65 years who had non-exudative forms of age-related macular degeneration (AMD), including 20 patients with degeneration of the retinal pigment epithelium (RPE), 15 with retinal drusen, and 5 with RPE atrophy were examined. All the patients were divided into 2 groups. Group 1 comprised 20 patients receiving, in addition to conventional therapy, cavinton forte (1 tablet contains 10 mg of vinpocetine). Group 2 (control) included 20 patients receiving conventional therapy (antioxidants, peptide bioregulators, lutein containing agents). Medical treatment was performed during 2 months. After a course of cavinton therapy, patients with AMD were observed to have better visual acuity, improved retinal function, and increased a- and b-wave amplitudes on a macular electroretinogram. There was improvement of ocular blood flow values, which is indicative of better uveal blood supply.

Cavinton for cerebral insufficiency
Cavinton forte treatment of cerebral vascular insufficiency in patients with coronary heart disease and arterial hypertension
Zh Nevrol Psikhiatr Im S S Korsakova. 2006.
Using 48-h Holter monitoring of ECG and ambulatory blood pressure monitoring, 28 patients (13 men, 15 women, mean age 66 years) with cerebral vascular insufficiency of the I-II stage in combination with chronic coronary heart disease and essential arterial hypertension were examined. Quantitative parameters of myocardial ischemia episodes and hypotension conditions were calculated and compared before the beginning (the first 24 h of monitoring) and during taking the daily dose of 30 mg of Cavinton forte (the second 24 hours of monitoring). The distribution of ischemia and hypotension episodes in the periods of the maximal supposed effect of the drug was analyzed. Cavinton forte neither contributes to the manifestation and average frequency of myocardial ischemia episodes nor influences parameters and the character of short-term arterial hypotension episodes. The drug reduces quantity and duration of blood pressure nocturnal fall. It is concluded that initial Cavinton forte treatment of cerebral vascular insufficiency in patients with chronic coronary heart disease in combination with arterial hypertension is safe when combined with hemodynamically active antihypertensive and antiischemic therapy.

Cavinton for hearing loss
Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis
Vestn Otorinolaringol. 2003.
According to pharmacological studies, cavinton has an effect on the end links of aminoglycosides interaction with elements of the internal ear. Basing on this property, cavinton was used as prophylaxis of neurosensory hypoacusis in 118 patients aged 17 to 63 years suffering from tuberculosis. The results of the studies have shown than cavinton not only prevents hypoacusis in patients with normal hearing but also improves it in patients with hearing problems.

The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing
Vestn Otorinolaringol. 2009; Afon'kin VIu, Dobretsov KG, Sipkin AV.
The objective of this study was to evaluate results of the new therapeutic modality for the management of chronic neurosensory loss of hearing based on the use of caviton. The open randomized study involved 50 patients. Criteria for the efficiency of therapy included the patients' complaints, self-evaluation of tympanophonia based on the visual-analogous scale, results of audiologic examination and Doppler ultrasound of carotid and vertebral arteries. Significant improvement of audiologic characteristics was documented in 80% of the patients; ultrasound examination showed that most of them tended to benefit from caviton therapy and reported reduction of tympanophonia. It is concluded that the new caviton dosing scheme for the treatment of neurosecretory loss of hearing is well tolerated by the patients and can be recommended for more extensive clinical application.

Cavinton for menopause symptoms
Complex effects of cavinton on climacteric symptoms
Akush Ginekol (Sofiia). 2001. Kolarov G, Orbetsova M, Nalbanski B, Kamenov Z, Georgiev S, Filipov E, Petrova Iu, Marinov B, Georgiev G.
The aim of the present study is to assess the therapeutic effect of Cavinton (vinpocetin) on the degree of climacteric symptoms and to verify its complex beneficial influence. The study comprises of three groups of women in early menopause--control group (n = 30), treatment groups with normolipidaemia and with hyperlipidaemia. All women presented with moderately expressed climacteric symptoms as assessed by Kupperman menopausal index and Hamilton-Anxiety-Skala (HAMA). The women in the 2nd and 3rd groups have been taking Cavinton in an oral dose of 5 mg three times daily for 3 months. Our data suggest that Cavinton possesses complex beneficial effects in climacteric women significantly ameliorating climacteric symptoms as well as some parameters of lipid metabolism in women with hyperlipidemia.

Is it okay to take Cavinton along with a bacopa monnieri pill?
    First find out how each one makes you feel and then when combining use smaller amounts of each supplement.